Asset Details
Do you wish to reserve the book?
FT538, iPSC‐derived NK cells, enhance AML cell killing when combined with chemotherapy
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
FT538, iPSC‐derived NK cells, enhance AML cell killing when combined with chemotherapy
Do you wish to request the book?
FT538, iPSC‐derived NK cells, enhance AML cell killing when combined with chemotherapy
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
FT538, iPSC‐derived NK cells, enhance AML cell killing when combined with chemotherapy
2025
Overview
Induced pluripotent stem cell (iPSC)–derived natural killer (NK) cells offer an opportunity for a standardized, off‐the‐shelf treatment with the potential to treat a wider population of acute myeloid leukaemia (AML) patients than the current standard of care. FT538 iPSC‐NKs express a high‐affinity, noncleavable CD16 to maximize antibody dependent cellular cytotoxicity, a CD38 knockout to improve metabolic fitness, and an IL‐15/IL‐15 receptor fusion preventing the need for cytokine administration, the main source of adverse effects in NK cell–based therapies. Here, we sought to evaluate the potential of FT538 iPSC‐NKs as a therapy for AML through their effect on AML cell lines and primary AML cells. We observed that FT538 iPSC‐NKs induce effector‐to‐target cell ratio dependent apoptosis in cell lines and primary AML cells, including cells from high‐risk patients. Flow cytometric analysis revealed that FT538 iPSC‐NKs induce AML cell death when combined with the AML therapies: cytarabine, venetoclax and gilteritinib. Moreover, cytarabine did not affect FT538 iPSC‐NK viability, suggesting that iPSC‐derived NK therapies and chemotherapy may be a promising treatment combination. This study provides the basis for further study of iPSC‐derived NK cell therapies as a treatment option for high‐risk AML patients, particularly those with disease resistant to standard therapies.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc
Subject
/ AML
/ Antigens
/ Bridged Bicyclo Compounds, Heterocyclic - pharmacology
/ Cytotoxicity, Immunologic - drug effects
/ Humans
/ Induced Pluripotent Stem Cells - cytology
/ Induced Pluripotent Stem Cells - immunology
/ Induced Pluripotent Stem Cells - metabolism
/ Killer Cells, Natural - drug effects
/ Killer Cells, Natural - immunology
/ Killer Cells, Natural - metabolism
/ Leukemia
/ Leukemia, Myeloid, Acute - drug therapy
/ Leukemia, Myeloid, Acute - immunology
/ Leukemia, Myeloid, Acute - pathology
/ Leukemia, Myeloid, Acute - therapy
/ Original
/ Patients
/ Toxicity
